Blueprint (Project Blueprint)

regimen · 2021–present

category:regimen

delivery:A daily regimen of diet (a fixed-calorie, largely plant-based meal plan), a supplement stack (marketed components have included a 'Longevity Mix' powder, softgel and capsule blends, high-polyphenol olive oil, collagen peptides, and a topical peptide serum and skincare line), structured exercise and sleep protocols, and periodic laboratory and imaging testing (blood panels, whole-body MRI, DNA-methylation 'epigenetic clock' testing, DEXA and other scans). Some components administered under Johnson's personal medical team went beyond consumer products into off-label prescription use (rapamycin, growth hormone) and a clinical procedure (therapeutic plasma exchange); those three have since been discontinued by Johnson himself. The commercial version sold to the public is the diet/supplement/testing subscription; the discontinued components were never sold to consumers as ongoing products.

price tier:elite

era:2021–present

current status:both

regulatory:supplement

SHORT PITCH (AS SOLD)

A comprehensive, heavily quantified diet-supplement-exercise-sleep regimen, developed and personally tested by tech entrepreneur Bryan Johnson and marketed as reducing 'biological age,' now sold as a consumer subscription product line.

THE ACTUAL EVIDENCE

The evidentiary base is Johnson's own self-reported, uncontrolled, N=1 measurements, tracked against DNA-methylation 'epigenetic clock' scores and other biomarker panels rather than against mortality or disease incidence. A peer-reviewed 2025 analysis of epigenetic clocks (Apsley et al., *Epigenomics*) concludes the clocks 'fail to meet common standards for clinical utility compared with established biomarkers' and that applying them in individual-level decision making 'can be uninformative and potentially harmful,' meaning they were not built, and have not been validated, to support individual-level anti-aging claims of the kind Blueprint's marketing makes. Independent experts quoted in the press (biologist Andrew Steele; epigenetic-aging researcher Morgan Levine) have specifically challenged the dosing evidence behind Blueprint's supplement capsules and the statistical basis of Johnson's headline 'pace of aging' claims. Three components of the regimen that Johnson personally trialed and publicized — young-donor plasma exchange, growth-hormone supplementation, and rapamycin — were each discontinued by Johnson after he reported no measured benefit or adverse effects, an unusually well-documented self-disconfirmation for a currently marketed product. No randomized controlled trial of the Blueprint protocol as a whole, on any endpoint, has been published.

PRACTITIONERS

Bryan Johnson

INGREDIENTS

Rapamycin (sirolimus)

CASES

johnson-blueprint-2021-present

CLAIMS

At the launch of Project Blueprint (October 2021), Johnson claimed a measured biological age of 36 against a chronological age of 44, and framed the goal as reversing the biological age of over 70 organs toward 'aging escape velocity.' unreplicated
Johnson has publicized a claim, widely reported in 2024, that he reduced his 'pace of aging' by 31 years relative to an average person. refuted
Beginning in early 2023, Johnson claimed that exchanging his blood plasma with that of a younger donor (including his then-17-year-old son) would improve his aging biomarkers. refuted
Blueprint markets its daily supplement and food stack (including a 'Longevity Mix' powder, 'essential capsules,' and high-polyphenol olive oil) as slowing or reversing biological aging. untested
As of Blueprint's January 2026 update, Johnson reports an epigenetic 'speed of aging' score of 0.48, telomere length equivalent to a 10-to-15-year-old, and a skin-age reduction from 64 to 36. unreplicated

SOURCES

NOTES

Blueprint began as Johnson’s personal experiment (announced 13 October 2021) and became a commercial company in 2024, when a 90-day, $333-a-month “Blueprint Basics” subscription opened to the first 2,500 sign-ups. By October 2025 the company had raised $60 million from a roster of celebrity and technology investors and hired an outside CEO, while continuing to sell the supplement, food, and testing product line built from Johnson’s protocol. The regimen’s evidentiary center of gravity has always been Johnson’s own body: the biomarker improvements he reports from DNA-methylation clocks, telomere assays, and organ-age estimates are the product’s primary marketing content, published on his own blog and amplified in press coverage and a Netflix documentary. That same self-experimentation record has also produced the case’s most unusual feature: Johnson has publicly discontinued three of the regimen’s more aggressive components (young-plasma exchange, growth hormone, rapamycin) after concluding, in his own words or through documented adverse effects, that they did not work or were not worth the risk, even as the consumer supplement and testing subscription continues to be sold on the strength of the same kind of uncontrolled, surrogate-endpoint evidence.